The Filing Desk

Inhibrx Biosciences

INBX · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

INBX · Last close · November 13, 2026
$83.30
Value Inhibrx Biosciences yourself

Inhibrx Biosciences' revenue rose 550.0% to $1 million in fiscal 2025. Its operating margin was −10,386.5%, up from −165,724.0% a year earlier. Free cash flow was −$130 million. The diluted share count rose 3.4%.

Inhibrx Biosciences, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 19, 2026 · 0002007919-26-000006 Updated
Revenue
$1M
550.0%
Operating margin
−10,386.5%
155337.5 pts
Net income
−$140M
$1.7B a year earlier
Free cash flow
−$130M
 
Return on equity
−197.8%
2103.8 pts
Market cap
$1.3B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Inhibrx Biosciences does

Inhibrx Biosciences is a clinical-stage drug company, which means it is testing experimental medicines in people and has none approved for sale. It builds protein-based drugs, called biologics, with its own protein engineering technology. Its drugs are built to attach to a target on cells in several places at once, in a way it believes is best for each target.

It has two drug candidates in human trials, both for cancer. Ozekibart (INBRX-109) acts on a cell receptor called DR5 and is being tested in chondrosarcoma, Ewing sarcoma, colorectal cancer and certain other solid tumors. INBRX-106 acts on a receptor called OX40 and is being tested in non-small cell lung cancer and head and neck squamous cell carcinoma. It also has a discovery pipeline of earlier programs.

The company was formed in May 2024, when the former Inhibrx, Inc. spun off these programs as Sanofi bought that company and took over its INBRX-101 therapy for a rare lung and liver disease. Inhibrx Biosciences has never earned revenue from product sales and has lost money since it started. It pays for its work by raising money from investors and through lending, licensing and collaboration deals.

Its biggest risks, as it describes them

  • Losses since it began and a limited operating history, with no revenue from product sales so far.
  • Candidates that may not prove safe or effective enough to win marketing approval.
  • Its protein engineering approach is novel and unproven, so cost, timing and success are hard to predict.
  • Needing more money, which could dilute shareholders or limit its operations.
  • Having only two drug candidates in human trials, so a setback for one would weigh heavily.
From Inhibrx Biosciences's annual report on Form 10-K, filed March 19, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Inhibrx Biosciences lost money in fiscal 2025: a net loss of $140 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments278153124
Debt incl. finance leases2070101
Net debt (negative means net cash)−71−153−24
Net debt to EBITDA———
Debt to equity4.8x0.0x12.6x
Interest coverage−6.9x−24.6x−11.1x
Current ratio5.2x3.9x3.9x
Quick ratio5.2x3.9x3.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Inhibrx Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Inhibrx Biosciences reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score—2 of 8
Rule of 40−98,591.9%−9,436.5%
Altman Z''−6.92−7.18
Accruals ratio770.3%−6.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positivePassFail
Cash from operations is positiveFailFail
Return on assets rose—Fail
Cash from operations exceeds net incomeFailPass
Debt fell relative to assets—Fail
Current ratio roseFailFail
Share count didn't riseFailFail
Gross margin rose——
Revenue rose relative to assets—Pass
F-score—2 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Inhibrx Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Inhibrx BiosciencesFY25550.0%−10,386.5%−9,986.5%——2
Z SquaredFY25—−956.9%————Compare
Celldex TherapeuticsFY25−78.0%−18,599.8%−13,829.1%———Compare
Shattuck LabsFY25−82.5%−5,150.8%−3,995.3%———Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue201
Revenue growth—−88.9%550.0%
Gross profit———
Research and development192204113
Operating income−219−331−135
Net income−2411,688−140
Diluted EPS (US$)−20.48112.62−9.04
Diluted shares (millions)121516
Cash flow
Cash from operations−193−194−130
Capital expenditure530
Free cash flow−198−197−130
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation255811
Balance sheet at fiscal year end
Cash and short-term investments278153124
Debt incl. finance leases2070101
Total assets308181146
Total liabilities26447138
Shareholders' equity441348
Margins and ratios
Gross margin———
Operating margin−12,178.9%−165,724.0%−10,386.5%
Net margin−13,408.9%843,786.0%−10,773.5%
Free cash flow margin−10,994.6%−98,503.0%−9,986.5%
Rule of 40 (growth + FCF margin)—−98,591.9%−9,436.5%
Return on capital———
Return on equity—1,905.9%−197.8%
Return on assets—690.7%−85.6%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Inhibrx Biosciences' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Inhibrx Biosciences.